Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
61 ECC5004 The preliminary results of the investigational agent ECC5004 phase 1 trial in non-human primates revealed a reduction in HbA1c levels, accompanied by weight loss and a decreased risk of adverse cardiovascular events, achieved through the mimicry of the hormone GLP-1
Regulatory agencies have previously found unlicensed weight loss treatments containing banned drugs like Sibutramine (a heart-risk stimulant removed from the market)
Understanding this established side effect profile provides important context when patients report symptoms that fall outside typical patterns, such as skin-related concerns
You might notice some initial improvement within a week
US$ 26.13
US$ 21.47
US$ 24.08
US$ 28.31
US$ 22.06
